Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric P Krenning

Showing results (41-50 of 173) with videos related to

Pageof 18
Sort By:
Accounts of Chemical Research|May 19, 2009
Tumor imaging and therapy using radiolabeled somatostatin analoguesMarion de Jong, Wout A P Breeman, Dik J Kwekkeboom, et al.
Cancer Medicine|April 24, 2025
Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [<sup>177</sup>Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 TrialMarianne Pavel, Martyn E Caplin, Philippe Ruszniewski, et al.
Journal of Radioanalytical and Nuclear Chemistry|July 31, 2015
Reduction of <sup>68</sup>Ge activity containing liquid waste from <sup>68</sup>Ga PET chemistry in nuclear medicine and radiopharmacy by solidificationErik de Blois, Ho Sze Chan, Kamalika Roy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2009
Kidney protection during peptide receptor radionuclide therapy with somatostatin analoguesEdgar J Rolleman, Marleen Melis, Roelf Valkema, et al.
Nuclear Medicine and Biology|August 21, 2007
Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differencesMarleen Melis, Eric P Krenning, Bert F Bernard, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imagingFlavio Forrer, Edgar Rolleman, Magda Bijster, et al.
Annals of the New York Academy of Sciences|May 22, 2004
Peptide receptor radionuclide therapyEric P Krenning, Dik J Kwekkeboom, Roelf Valkema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2013
99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluationPanteleimon J Marsouvanidis, Theodosia Maina, Werner Sallegger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2003
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activitiesWouter A P Breeman, Marion De Jong, Theo J Visser, et al.
Anti-Cancer Drugs|December 1, 2005
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion methodFrederike K Engels, Dirk Buijs, Walter J Loos, et al.
Pageof 18

Showing results (41-50 of 173) with videos related to

Sort By:
Pageof 18
Accounts of Chemical Research|May 19, 2009
Tumor imaging and therapy using radiolabeled somatostatin analoguesMarion de Jong, Wout A P Breeman, Dik J Kwekkeboom, et al.
Cancer Medicine|April 24, 2025
Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [<sup>177</sup>Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 TrialMarianne Pavel, Martyn E Caplin, Philippe Ruszniewski, et al.
Journal of Radioanalytical and Nuclear Chemistry|July 31, 2015
Reduction of <sup>68</sup>Ge activity containing liquid waste from <sup>68</sup>Ga PET chemistry in nuclear medicine and radiopharmacy by solidificationErik de Blois, Ho Sze Chan, Kamalika Roy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2009
Kidney protection during peptide receptor radionuclide therapy with somatostatin analoguesEdgar J Rolleman, Marleen Melis, Roelf Valkema, et al.
Nuclear Medicine and Biology|August 21, 2007
Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differencesMarleen Melis, Eric P Krenning, Bert F Bernard, et al.
Cancer Biotherapy & Radiopharmaceuticals|July 14, 2007
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imagingFlavio Forrer, Edgar Rolleman, Magda Bijster, et al.
Annals of the New York Academy of Sciences|May 22, 2004
Peptide receptor radionuclide therapyEric P Krenning, Dik J Kwekkeboom, Roelf Valkema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2013
99mTc radiotracers based on human GRP(18-27): synthesis and comparative evaluationPanteleimon J Marsouvanidis, Theodosia Maina, Werner Sallegger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2003
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activitiesWouter A P Breeman, Marion De Jong, Theo J Visser, et al.
Anti-Cancer Drugs|December 1, 2005
Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion methodFrederike K Engels, Dirk Buijs, Walter J Loos, et al.
Pageof 18